Home
/
REGENERON PHARMACEUTICALS, INC.
/
Financials
/
Quarterly
REGENERON PHARMACEUTICALS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that REGENERON PHARMACEUTICALS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$1.51B
May 3, 2018
Q3
2017
Sep 30, 2017
$1.50B
Nov 8, 2017
Q2
2017
Jun 30, 2017
$1.47B
Aug 3, 2017
Q1
2018
Mar 31, 2017
$1.32B
May 3, 2018
Q3
2017
Sep 30, 2016
$1.22B
Nov 8, 2017
Q2
2017
Jun 30, 2016
$1.21B
Aug 3, 2017
Q1
2017
Mar 31, 2016
$1.20B
May 4, 2017
Q3
2016
Sep 30, 2015
$1.14B
Nov 4, 2016
Q2
2016
Jun 30, 2015
$998.62M
Aug 4, 2016
Q1
2016
Mar 31, 2015
$869.61M
May 5, 2016
Q3
2015
Sep 30, 2014
$725.79M
Nov 4, 2015
Q2
2015
Jun 30, 2014
$665.70M
Aug 4, 2015
Q1
2015
Mar 31, 2014
$625.74M
May 7, 2015
Q3
2014
Sep 30, 2013
$597.03M
Nov 4, 2014
Q2
2014
Jun 30, 2013
$457.64M
Aug 5, 2014
Q1
2014
Mar 31, 2013
$439.66M
May 8, 2014
Q3
2013
Sep 30, 2012
$427.69M
Nov 5, 2013
Q2
2013
Jun 30, 2012
$304.40M
Aug 6, 2013
Q1
2013
Mar 31, 2012
$231.79M
May 3, 2013
Q3
2012
Sep 30, 2011
$102.83M
Oct 24, 2012
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$3.75B
Oct 28, 2025
Q2
2025
Jun 30, 2025
$3.68B
Aug 1, 2025
Q1
2025
Mar 31, 2025
$3.03B
Apr 29, 2025
Q3
2025
Sep 30, 2024
$3.72B
Oct 28, 2025
Q2
2025
Jun 30, 2024
$3.55B
Aug 1, 2025
Q1
2025
Mar 31, 2024
$3.15B
Apr 29, 2025
Q3
2024
Sep 30, 2023
$3.36B
Oct 31, 2024
Q2
2024
Jun 30, 2023
$3.16B
Aug 1, 2024
Q1
2024
Mar 31, 2023
$3.16B
May 2, 2024
Q3
2023
Sep 30, 2022
$2.94B
Nov 2, 2023
Q2
2023
Jun 30, 2022
$2.86B
Aug 3, 2023
Q1
2023
Mar 31, 2022
$2.97B
May 4, 2023
Q3
2022
Sep 30, 2021
$3.45B
Nov 3, 2022
Q2
2022
Jun 30, 2021
$5.14B
Aug 3, 2022
Q1
2022
Mar 31, 2021
$2.53B
May 4, 2022
Q3
2021
Sep 30, 2020
$2.29B
Nov 4, 2021
Q2
2021
Jun 30, 2020
$1.95B
Aug 5, 2021
Q1
2021
Mar 31, 2020
$1.83B
May 6, 2021
Q3
2020
Sep 30, 2019
$1.74B
Nov 5, 2020
Q2
2020
Jun 30, 2019
$1.58B
Aug 5, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$1.46B
Oct 28, 2025
Q3
2025
Jun 30, 2025
$1.39B
Oct 28, 2025
Q2
2025
Jun 30, 2025
$1.39B
Aug 1, 2025
Q2
2025
Mar 31, 2025
$808.70M
Aug 1, 2025
Q3
2025
Mar 31, 2025
$808.70M
Oct 28, 2025
Q1
2025
Mar 31, 2025
$808.70M
Apr 29, 2025
Q3
2025
Sep 30, 2024
$1.34B
Oct 28, 2025
Q3
2025
Jun 30, 2024
$1.43B
Oct 28, 2025
Q2
2025
Jun 30, 2024
$1.43B
Aug 1, 2025
Q1
2025
Mar 31, 2024
$722.00M
Apr 29, 2025
Q2
2025
Mar 31, 2024
$722.00M
Aug 1, 2025
Q3
2025
Mar 31, 2024
$722.00M
Oct 28, 2025
Q3
2024
Sep 30, 2023
$1.01B
Oct 31, 2024
Q3
2024
Jun 30, 2023
$968.40M
Oct 31, 2024
Q2
2024
Jun 30, 2023
$968.40M
Aug 1, 2024
Q1
2024
Mar 31, 2023
$817.80M
May 2, 2024
Q2
2024
Mar 31, 2023
$817.80M
Aug 1, 2024
Q3
2024
Mar 31, 2023
$817.80M
Oct 31, 2024
Q3
2023
Sep 30, 2022
$1.32B
Nov 2, 2023
Q3
2023
Jun 30, 2022
$852.10M
Nov 2, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$1.03B
Oct 28, 2025
Q2
2025
Jun 30, 2025
$1.08B
Aug 1, 2025
Q1
2025
Mar 31, 2025
$591.70M
Apr 29, 2025
Q3
2025
Sep 30, 2024
$1.18B
Oct 28, 2025
Q2
2025
Jun 30, 2024
$1.07B
Aug 1, 2025
Q1
2025
Mar 31, 2024
$751.40M
Apr 29, 2025
Q3
2024
Sep 30, 2023
$1.11B
Oct 31, 2024
Q2
2024
Jun 30, 2023
$1.02B
Aug 1, 2024
Q1
2024
Mar 31, 2023
$946.70M
May 2, 2024
Q3
2023
Sep 30, 2022
$1.22B
Nov 2, 2023
Q2
2023
Jun 30, 2022
$1.11B
Aug 3, 2023
Q1
2023
Mar 31, 2022
$1.26B
May 4, 2023
Q3
2022
Sep 30, 2021
$1.85B
Nov 3, 2022
Q2
2022
Jun 30, 2021
$3.35B
Aug 3, 2022
Q1
2022
Mar 31, 2021
$1.11B
May 4, 2022
Q3
2021
Sep 30, 2020
$1.05B
Nov 4, 2021
Q2
2021
Jun 30, 2020
$656.40M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$700.10M
May 6, 2021
Q3
2020
Sep 30, 2019
$738.50M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$315.60M
Aug 5, 2020